Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.

Development of a recombinant replication-deficient rabies virus-based bivalent-vaccine against MERS-CoV and rabies virus and its humoral immunogenicity in mice.

Middle East respiratory syndrome-coronavirus (MERS-CoV) is an emerging virus that causes severe disease with fatal outcomes; however, there are currently no approved vaccines or specific treatments against MERS-CoV. Here, we developed a novel bivalent vaccine against MERS-CoV and rabies virus (RV) u...

Full description

Bibliographic Details
Main Authors: Hirofumi Kato, Mutsuyo Takayama-Ito, Itoe Iizuka-Shiota, Shuetsu Fukushi, Guillermo Posadas-Herrera, Madoka Horiya, Masaaki Satoh, Tomoki Yoshikawa, Souichi Yamada, Shizuko Harada, Hikaru Fujii, Miho Shibamura, Takuya Inagaki, Kinjiro Morimoto, Masayuki Saijo, Chang-Kweng Lim
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2019-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0223684

Internet

https://doi.org/10.1371/journal.pone.0223684

Similar Items